@FiercePharma: Abbott CEO pay drops 7% to $26.2 mil. News | Follow @FiercePharma
> Alpharma, a unit of King Pharmaceuticals, has agreed to pay $42.5 million to resolve allegations that it gave kickbacks to doctors to prescribe the pain drug Kadian and misrepresented its safety and effectiveness, the Justice Department said. Release
> The World Health Organization has suspended the distribution and purchase of the Shan5 vaccine, produced by Sanofi-Aventis's Indian unit Shantha Biotechnics, pending a quality investigation. Report
> The FDA Tuesday ordered Glenmark Generics of Mahwah, N.J., and Konec of Tucson, Ariz., to stop marketing unapproved nitroglycerin tablets. The tablets are placed under the tongue to relieve chest pain or to stop a heart attack and are marketed in 0.3-, 0.4- and 0.6-mg dosages. Release
> Shire has received a Paragraph IV notice letter from Teva Pharmaceuticals USA, advising of the filing of an ANDA for a generic version of Shire's 1, 2, 3 and 4 mg guanfacine HCl extended release tablets, INTUNIV. Release
> Teva Pharmaceutical Industries announced today that the parties to the patent litigation regarding Barr's U.S. generic version of Schering's Temodar have entered an agreement pending resolution of Schering's appeal to the Federal Circuit of the U.S. District Court's decision holding the '291 Patent unenforceable. Release
> The FDA hit three companies with warning letters for promotional materials on three drugs and requested corrective communications for all three. Report
> Ranbaxy Laboratories settled a patent dispute with Takeda Pharmaceutical, allowing it to sell a generic of the diabetes blockbuter Actos by August 2012. Report
> Simcere Pharmaceutical Group's fourth-quarter earnings dropped by two-thirds as the Chinese pharmaceutical company saw higher costs that more than offset a double-digit revenue jump. Report
> Roche has asked FDA for permission to market its Actemra rheumatoid arthritis treatment as a means of preventing structural damage in patients with the potentially crippling disease. Report
Biotech News
@FierceBiotech: BioTime shares soar as researchers reverse cell aging. Report | Follow @FierceBiotech
@JohnCFierce: Derek Lowe explains in concise terms why BioTime's cell aging work has a long, long way to go. Item | Follow @JohnCFierce
> Roche pipeline close-up will focus on Phase III blockbusters. Report
> Cash squeeze triggers going-concern alert at Molecular Insight. Story
> Human Genome Sciences announced this morning that its cancer antibody flunked a mid-stage clinical trial, failing to produce better data on either disease response or progression-free survival for lung cancer when compared to a control group. Article
> Novartis reports Phase II success with novel blood pressure drug. Item
> Unigene Labs raises $13.6 million in debt restructuring. Story
And Finally ... The elderly are not treated as aggressively for colon cancer as younger people, even though clinical trials show that the treatments are equally successful for them. Report